Ken Johnson, Pharm.D.
Senior Vice President, Global Development and Medical Affairs
Dr. Ken Johnson currently serves as the Senior Vice President, Global Development and Medical Affairs of Xeris Pharmaceuticals. Dr. Johnson is responsible for leading clinical and nonclinical development, regulatory, quality and medical affairs to effectively generate high-quality scientific and clinical evidence for Xeris' products to support product approval, advance clinical education and practice, inform policy, and improve health outcomes for patients.
Dr. Johnson has more than 30 years of professional experience in the pharmaceutical industry, pharmaceutical benefits management, and academia. Dr. Johnson was most recently Executive Director, US Medical Affairs for Hospital Specialty Products at Merck. Previously, Dr. Johnson held senior management positions in Medical Affairs and Outcomes Research at Circassia Pharmaceuticals, Durata Therapeutics, Horizon Pharma, Takeda Pharmaceuticals North America, NeoPharm, Searle/Pharmacia, and Bristol-Myers Squibb. He also served as Vice President, Analytics and Outcomes Research at Caremark, working with Fortune 200 employers and other pharmacy benefit purchasers. Dr. Johnson began his professional career on the faculty at the University of Colorado School of Pharmacy, with a practice and research focus in therapeutic drug monitoring and clinical pharmacokinetics.
Dr. Johnson has established de novo Medical Affairs and Outcomes Research functions for four emerging biopharmaceutical companies. In addition, he has established and led regional Medical Affairs teams for both large global and emerging biopharmaceutical companies. Throughout his career, Dr. Johnson has consistently been recognized for his leadership, strategic thinking, collaboration, and ability to innovate across a broad range of organizations.
Dr. Johnson received his Doctor of Pharmacy from the University of Minnesota and completed a postdoctoral fellowship at the University of Tennessee Health Sciences Center. Dr. Johnson holds a number of adjunct academic appointments and is a member of several professional societies.
Dr. Johnson has more than 30 years of professional experience in the pharmaceutical industry, pharmaceutical benefits management, and academia. Dr. Johnson was most recently Executive Director, US Medical Affairs for Hospital Specialty Products at Merck. Previously, Dr. Johnson held senior management positions in Medical Affairs and Outcomes Research at Circassia Pharmaceuticals, Durata Therapeutics, Horizon Pharma, Takeda Pharmaceuticals North America, NeoPharm, Searle/Pharmacia, and Bristol-Myers Squibb. He also served as Vice President, Analytics and Outcomes Research at Caremark, working with Fortune 200 employers and other pharmacy benefit purchasers. Dr. Johnson began his professional career on the faculty at the University of Colorado School of Pharmacy, with a practice and research focus in therapeutic drug monitoring and clinical pharmacokinetics.
Dr. Johnson has established de novo Medical Affairs and Outcomes Research functions for four emerging biopharmaceutical companies. In addition, he has established and led regional Medical Affairs teams for both large global and emerging biopharmaceutical companies. Throughout his career, Dr. Johnson has consistently been recognized for his leadership, strategic thinking, collaboration, and ability to innovate across a broad range of organizations.
Dr. Johnson received his Doctor of Pharmacy from the University of Minnesota and completed a postdoctoral fellowship at the University of Tennessee Health Sciences Center. Dr. Johnson holds a number of adjunct academic appointments and is a member of several professional societies.